Brand-name prescription drug pricing : lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases : report to congressionals requesters.

Brand-name prescription drug pricing : lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases : report to congressionals requesters.

Bibliographic Details
Corporate Author: United States. Government Accountability Office
Format: Government Document eBook
Language:English
Published: [Washington, D.C.] : U.S. Govt. Accountability Office, [2009]
Subjects:
Prescription pricing.
Brand name products > Prices.
Prescription pricing > Government policy > United States.
Online Access:https://purl.fdlp.gov/GPO/LPS121786

Internet

https://purl.fdlp.gov/GPO/LPS121786

Available Online

Holdings details from Available Online
Call Number: GA 1.13:GAO-10-201
 
Call Number Status Get It
GA 1.13:GAO-10-201 Available